Main content

    Ovarian Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
    Description: Study for Women With Platinum Sensitive Ovarian Cancer Evaluating Niraparib as Maintenance Therapy
    Investigator: John Chan, MD
    Eligibility: Subjects with platinum sensitive ovarian cancer who completed at least 2 lines of platinum therapy
    Status: Active and open to enrollment
    Contact: Lilian Hu, MPH, 415-600-3241 Email: HuLH@cpmcri.org about Study Tesaro PR-30-5011-C

    Title: EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
    Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472 Email: GasperJP@cpmcri.org about Study EAY131 NCI-MATCH

    Title: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer
    Description: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
    Investigator: Ari Baron, MD
    Eligibility: Subjects with platinum-resistant ovarian cancer
    Status: Closed to enrollment
    Contact: Lilian Hu, MPH, 415-600-3241 Email: HuLH@cpmcri.org about Study Endocyte EC-FV-06

    • updated Sept. 2, 2015

    Back to top